PROJECT

Projects

Summary of Investment Information

Project Number

45021

Company Name

SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.

Date SPI Disclosed

May 25, 2021

Country

China

Region

East Asia and the Pacific

Projected Board Date

Apr 30, 2021

Environmental Category

B - Limited

Status

Active

Last Updated Date

Jul 1, 2021

Department

Regional Industry - MAS Asia & Pac

Industry

other

Previous Events

Approved : May 4, 2021
Signed : May 25, 2021
Invested : Jun 29, 2021

Sector

other

Project Description

 Shanghai Fosun Pharmaceutical (Group) Co. Ltd., (“Fosun Pharma”, or the “Company”) is a leading manufacturer of pharmaceutical products and medical devices in China. The Company’s business spans across the healthcare value chain from research & development, pharmaceutical manufacturing, medical devices and diagnosis, to healthcare services, pharmaceutical distribution and retail. Fosun Pharma has been listed on the Shanghai Stock Exchange since 1998 and Hong Kong Stock Exchange since 2012.

 

The proposed IFC investment will primarily support Fosun Pharma’s manufacturing and distribution of COVID-19 related medical products, including the COVID-19 vaccine co-developed by Pfizer / BioNTech and COVID-19 testing kits and in China (the “Project”).

Associated Advisory Engagement

                                

Sponsor / Cost / Location

Development Impact

E&S Category Rationale / Risks and Mitigation